AZD-9496

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H25F3N2O2
Molecular Weight	442.4734
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1CC2=C(NC3=C2C=CC=C3)[C@H](N1CC(C)(C)F)C4=C(F)C=C(\C=C\C(O)=O)C=C4F

InChI

InChIKey=DFBDRVGWBHBJNR-BBNFHIFMSA-N

InChI=1S/C25H25F3N2O2/c1-14-10-17-16-6-4-5-7-20(16)29-23(17)24(30(14)13-25(2,3)28)22-18(26)11-15(12-19(22)27)8-9-21(31)32/h4-9,11-12,14,24,29H,10,13H2,1-3H3,(H,31,32)/b9-8+/t14-,24-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C25H25F3N2O2
Molecular Weight	442.4734
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT02780713 | https://www.ncbi.nlm.nih.gov/pubmed/26407012

AZD 9496 was discovered by AstraZeneca as a potent and selective estrogen receptor downregulator (SERD). This drug participated in phase I clinical trials to evaluate the pharmacokinetic profiles and the safety and tolerability of the different forms, formulations, and doses for the treatment of patients with breast cancer.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Estrogen receptor alpha 134 Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27020862	Antagonist 2849		0.28 nM [IC50]

PubMed

Title	Date	PubMed
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.	2019-02	30555156
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.	2018-12-01	30082476
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.	2016-06-01	27020862
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.	2015-10-22	26407012

Sample Use Guides

In Vivo Use Guide

1.Treatment period 1 will assess AZD9496 Variant A: 100mg. 2.Treatment period 2 will assess AZD9496 Reference: 100mg. 3.Treatment period 3 will assess one of AZD9496 Variants, B, C or D: 100mg. 4.Treatment period 4 will assess one of AZD9496 Variants, B, C or D: 100mg.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:17:04 GMT 2025` Edited by `admin` on `Mon Mar 31 22:17:04 GMT 2025`
Record UNII	DA9P7LN909
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZD-9496

Common Name

English

AZD9496

Preferred Name

English

2-PROPENOIC ACID, 3-(3,5-DIFLUORO-4-((1R,3R)-2-(2-FLUORO-2-METHYLPROPYL)-2,3,4,9-TETRAHYDRO-3-METHYL-1H-PYRIDO(3,4-B)INDOL-1-YL)PHENYL)-, (2E)-

Systematic Name

English

(2E)-3-(3,5-DIFLUORO-4-((1R,3R)-2-(2-FLUORO-2-METHYLPROPYL)-2,3,4,9-TETRAHYDRO-3-METHYL-1H-PYRIDO(3,4-B)INDOL-1-YL)PHENYL)-2-PROPENOIC ACID

Systematic Name

English

SELECTIVE ESTROGEN RECEPTOR DEGRADER AZD9496

Common Name

English

AZD 9496 [WHO-DD]

Common Name

English

(E)-3-(3,5-DIFLUORO-4-((1R,3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2,3,4,9-TETRAHYDRO-1H-PYRIDO(3,4-B)INDOL-1-YL)PHENYL)ACRYLIC ACID

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2116